China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of understanding (MOU) with Thailand’s Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Genomics Innovation Public Company Limited, and Hemogen Hongkong Alpha Technology., Ltd. The collaboration aims to enhance the prevention and treatment of Thalassemia and to jointly develop cell and gene therapy (CGT) solutions.
Combating Thalassemia: A Joint Effort
Thalassemia, a disease with high incidence rates in Thailand, poses a significant challenge to the nation’s healthcare system. This strategic partnership will assess the comparative scope, efficiency, outcomes, and health economic benefits of high-throughput sequencing technology-based Thalassemia gene screening against traditional methods. Additionally, the collaboration will extend to clinical trial cooperation for gene therapy in Thalassemia within Thailand.
The Impact of Thalassemia in Thailand
Thalassemia and sickle anemia are widespread in Thailand, affecting approximately 1% of the population and making it a critical public health issue. It is estimated that 30% to 40% of Thailand’s population are carriers of the Thalassemia gene, which can result in over 60 different genotypes with clinical manifestations varying from asymptomatic to fatal. BGI Genomics’ high-throughput sequencing technology-based genetic testing kit is capable of detecting hemoglobin diseases, including Thalassemia and sickle anemia, simultaneously.
Advancing Genomic Solutions for Public Health
The MOU signifies a significant step forward in the fight against Thalassemia, leveraging BGI Genomics’ expertise in genomics to improve diagnostics and therapeutics. The collaboration not only seeks to enhance current screening and treatment methods but also to pioneer new approaches in gene therapy, potentially offering groundbreaking solutions to manage this prevalent genetic disorder in Thailand.-Fineline Info & Tech
